Publix recalled Greenwise baby food pouches due to elevated lead levels. What to know
Check your shelves: Publix recalled one of its Greenwise baby food pouches due to the potential of elevated levels of lead contamination.
The Florida-based grocery store chain initiated a voluntary recall on May 9 for GreenWise Pear, Kiwi, Spinach & Pea Baby Food, from Bowman Andros LLC, a fruit processing factory in Virginia.
Even low levels of lead have been shown to affect learning and the ability to pay attention, according to the Centers for Disease Control and Prevention. Most children exposed to lead have no obvious immediate symptoms and may need a blood lead test.
'As part of our commitment to food safety, potentially impacted products have been removed from all store shelves,' said Publix Director of Communications Maria Brous in a release. 'To date, there have been no reported cases of illness."
The recall comes just under a month after Target recalled one of its own store-brand baby food products due to elevated lead levels. The national chain recalled 26,500 units of Good & Gather baby Pea, Zucchini, Kale & Thyme Vegetable Purèe from Miami-based Fruselva USA.
Food safety: FDA suspends food safety quality checks. How to protect yourself from salmonella, listeria
GreenWise Pear, Kiwi, Spinach & Pea Baby Food, 4 oz.
The items have a GTIN number of 41415-00901 and a "Best If" date of 11/01/2025.
Stop using it immediately. If you suspect your child has been exposed to lead, talk to their healthcare provider.
Consumers who have purchased the product in question may return the product to their local store for a full refund. Publix customers with additional questions may call the customer care department at 800-242-1227 or visit publix.com.
This article originally appeared on The Daytona Beach News-Journal: Publix baby food recall: Elevated Greenwise lead levels found
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
UPI
42 minutes ago
- UPI
NIH office to phase out HIV guidelines by next year
The National Institutes of Health office responsible for issuing federal guidelines related to treatment of HIV and AIDS patients in the United States is making major changes. File Photo by Annabelle Gordon/UPI | License Photo June 21 (UPI) -- The National Institutes of Health office responsible for issuing federal guidelines related to treatment of HIV and AIDS patients in the United States is making major changes. The NIH Office of AIDS Research or OAR told its employees this week it intends to phase out the guidelines by next June, the Washington Post reported, citing an internal staff email. According to the office, OAR "coordinates HIV/AIDS research across the National Institutes of Health and provides the largest public investment in HIV/AIDS research globally." "In the climate of budget decreases and revised priorities, OAR is beginning to explore options to transfer management of the guidelines to another agency within" the letter obtained by The Post reads. The OAR guidelines contain guidelines related to diagnosis and treatments of HIV and AIDS. There are currently more than 1 million people living with HIV in the United States. It was not immediately clear what the other agency referred to in the letter was or how such a move may affect the guideline, the Post reported. The news comes as President Donald Trump and Secretary of State Marco Rubio move to cut over $8 billion from the U.S. Agency for International Development, USAID and merge it into the State Department. State Department officials say the move comes with the expectation that other countries will increase their roles in delivering aid around the world. An April report published in the Lancet medical journal found around half a million children globally could die from AIDS by 2030 if the United States cuts its global relief funding. Earlier this week, the U.S. Food and Drug Administration approved use of the HIV drug lenacapavir, which is produced by California-based biopharma firm Gilead Sciences under the name Yeztugo. "Yeztugo is one of the most important scientific breakthroughs of our time and offers a very real opportunity to help end the HIV epidemic," Gilead Science Chairman and Chief Executive Officer Daniel O'Day said in a statement on the company's website
Yahoo
5 hours ago
- Yahoo
Ascension Sacred Heart Pensacola earns top maternity accreditation
PENSACOLA, Fla. (WKRG) — The Joint Commission has awarded Ascension Sacred Heart Pensacola a Level IV verification for Maternal Levels of Care, has learned. The hospital reportedly is one of just 10 Florida hospitals to earn Level IV accreditation. GoFundMe started for family of woman who died in boating accident at Bayou Sara The award recognizes Sacred Heart's ability to provide comprehensive care for mothers and infants across all levels of need and risk. Sacred Heart Pensacola earned the highest tier of accreditation after undergoing two days of rigorous in-person examination by a Joint Commission surveyor, according to a news release. Level IV status represents that the hospital provides comprehensive on-site medical and surgical care for complicated maternal conditions throughout all stages of a woman's pregnancy, according to the release. Kristina Lapeyrouse of Baker High School 'Securing the highest level of verification assures our community that our maternal and pediatric care teams are some of the best in the country,' said Dr. William J. Schwartz III, Medical Director of Maternal-Fetal Medicine at Sacred Heart Pensacola. Sacred Heart's facilities serve as regional perinatal health care centers, offering high-quality and accessible care, officials said. 'Earning an accreditation of this stature instills a tremendous sense of joy and confidence in all of our maternal care associates,' said Niki Dey, director of Women's Services at Sacred Heart Pensacola. Sacred Heart Pensacola aims to address key obstacles to maternal care, such as transportation, insurance, financial assistance, and childcare, officials said. Mobile teen to compete in national scholarship program finals this month To learn more about Ascension Sacred Heart, visit the hospital's website. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
7 hours ago
- Yahoo
After her heart started to fail, a first-of-its-kind surgery saved her life
Sue Baker was used to spending time in the hospital. She had started having heart troubles in 2015, and as the issue escalated, she spent more and more time in the hospital. She had a pacemaker implanted to keep her heart beating. Once, she spent five days in a coma. In 2019, as her heart function continued to fail, Baker received a left ventricular assist device, or LVAD, a mechanical pump that helps the heart's left ventricle circulate blood throughout the body. For years, Baker lived on "batteries and electricity," but she didn't stop living her life. She married a man she loved, and they started building a life together in southeast Georgia. However, she knew the LVAD was only a stopgap measure, and wanted to make sure she was living a full life before her health declined further. Four years after getting the LVAD, Baker started having dangerous heart rhythms. She was admitted to the Mayo Clinic in Jacksonville, Florida, and was added to the transplant list to await a new heart. For months, the 58-year-old waited, often receiving painful shocks from her LVAD and pacemaker as they tried to keep her heart functioning. Her body was also producing too many antibodies, which put her at high risk for rejecting any organs she received. Her transplant cardiologist, Dr. Pareg Patel, tested multiple medications, including chemotherapies, to reduce the antibodies. The process was "very scary," she said. One day, Patel came to her with another option: She could have a liver transplant, in addition to the new heart. It might solve the antibody problem. There was just one catch: A heart-liver transplant had never been done in someone with an LVAD before. Her other option was palliative care. "We got to talking about it, and I was like 'You're not going to know unless somebody agrees to do this. There's not much choice, really,'" Baker recalled. "It was going to be an experiment one way or the other." A first-of-its-kind transplant The liver is "like sponges that take down these antibodies," Patel explained. Sometimes, livers are transplanted alongside hearts to lower the risk of rejection. But the procedure means a patient needs to wait until a heart and liver are available from the same donor. Some people die on the waiting list, Patel said. But for Baker, it was the best option. "It's a story where we were able to find an out-of-the-box solution for somebody who I can guarantee you two years ago we would have said no to and put them in hospice," Patel said. "She had less than probably six months to live in, more likely three months." Baker spent months in the hospital, continuing to receive painful shocks from her LVAD and pacemaker. She had other complications, including diagnoses of COVID-19 and pneumonia. In September 2024, she finally received word that a heart and liver were available to her. "I was shocked," Baker said. "I was so excited." Patel said he and his team anticipated that the surgery would be "challenging" and "very high risk" because of Baker's health complications but everyone believed it was the best possible option. Baker would also be donating her "perfectly healthy" liver to another patient, Patel said, in what's known as a domino operation. "I think the cool part of this is for Sue, is that by using this technology, number one, we were able to prove that by placing a liver and a heart from somebody is we're able to make antibodies go close to zero," Patel explained. "And number two, we were able to have Sue become not only a recipient of two organs, but also a donor in the same day." Blazing a path for other patients After her surgery, Baker said she had a long recovery, but spent her time in the hospital bonding with other patients. She tried to be a voice of optimism for other people waiting for transplants, she said. She also received a letter from the person who received her liver. After Baker recovered and left the hospital in October 2024, she was eager to resume her life in Georgia, but tragedy struck: Her husband died from a sudden cardiac arrest just weeks later. Burdened by medical bills and funeral expenses, her financial situation spiraled. She said her housing is now unstable, and most spare money goes to flying to regular check-ups at the Mayo Clinic. A GoFundMe has only raised a few hundred dollars. Patel said Baker will need frequent check-ups and medication to maintain her new organs. Mayo Clinic said it offers financial assistance and payment plan options, as well as financial counseling to patients who are uninsured or underinsured. Baker said she is leaning on her church for emotional support and other aid. She has a caretaker, Charlene, who helps with day-to-day life. She also hopes that her taking part in the first-of-its-kind surgery will allow more people to receive lifesaving treatment, and said the thought brings her some solace. Patel said that another surgery like Baker's was already conducted, and that another is in the works. "If it weren't for her, these other two patients would have no opportunity," Patel said. "Doing what I did, it opened it up for so many more patients," Baker said. "It made me very happy to know that more LVAD patients will be able to go through this and actually have a long chance at life." Iran and Israel exchange fire; Israel intensifies air assault on Gaza Columbia activist Mahmoud Khalil released on bail Trump continues to weigh U.S. intervention in Iran
